Mohamed H Sayegh

List of Publications by Year
in descending order

253	26,931	4388 86	6300 158
papers	citations	h-index	g-index

258	258	258	20660
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of cells initiating human melanomas. Nature, 2008, 451, 345-349.	27.8	1,327
2	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	8.5	1,042
3	Delayed graft function in kidney transplantation. Lancet, The, 2004, 364, 1814-1827.	13.7	828
4	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. Journal of Experimental Medicine, 2003, 198, 63-69.	8.5	697
5	The Role of T-Cell Costimulatory Activation Pathways in Transplant Rejection. New England Journal of Medicine, 1998, 338, 1813-1821.	27.0	547
6	ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma. Cancer Research, 2005, 65, 4320-4333.	0.9	537
7	Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nature Medicine, 2000, 6, 464-469.	30.7	491
8	Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question. Journal of Immunology, 2001, 166, 973-981.	0.8	469
9	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	8.5	461
10	Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nature Medicine, 1998, 4, 1392-1396.	30.7	451
11	Anaritide in Acute Tubular Necrosis. New England Journal of Medicine, 1997, 336, 828-834.	27.0	447
12	Immunomodulation by Mesenchymal Stem Cells. Diabetes, 2008, 57, 1759-1767.	0.6	445
13	Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. Journal of Clinical Investigation, 2011, 121, 3645-3656.	8.2	416
14	Immunosuppressive strategies in transplantation. Lancet, The, 1999, 353, 1083-1091.	13.7	395
15	Homeostatic proliferation is a barrier to transplantation tolerance. Nature Medicine, 2004, 10, 87-92.	30.7	388
16	A critical role for the programmed death ligand 1 in fetomaternal tolerance. Journal of Experimental Medicine, 2005, 202, 231-237.	8.5	375
17	EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1. Transplantation, 1998, 65, 1533-1542.	1.0	373
18	Transplantation 50 Years Later â€" Progress, Challenges, and Promises. New England Journal of Medicine, 2004, 351, 2761-2766.	27.0	364

#	Article	IF	Citations
19	Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. Journal of Immunology, 2009, 183, 993-1004.	0.8	355
20	A Novel Mechanism of Action for Anti-Thymocyte Globulin. Journal of the American Society of Nephrology: JASN, 2006, 17, 2844-2853.	6.1	352
21	Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 ⁺ CD4 ⁺ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9331-9336.	7.1	348
22	Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. Journal of Experimental Medicine, 1998, 187, 2037-2044.	8.5	328
23	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1â€“PD-L1 pathway. Journal of Experimental Medicine, 2006, 203, 2737-2747.	8.5	280
24	A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. Journal of Experimental Medicine, 2008, 205, 3133-3144.	8.5	277
25	INDIRECT ALLORECOGNITION OF MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES IN HUMAN RENAL TRANSPLANT RECIPIENTS WITH CHRONIC GRAFT DYSFUNCTION1. Transplantation, 1997, 64, 795-800.	1.0	268
26	Calcineurin Inhibitors: 40 Years Later, Canâ€™t Live Without â€¦. Journal of Immunology, 2013, 191, 5785-5791.	0.8	256
27	Favorably Tipping the Balance between Cytopathic and Regulatory T Cells to Create Transplantation Tolerance. Immunity, 2003, 19, 503-514.	14.3	245
28	Immunologic Tolerance to Renal Allografts after Bone Marrow Transplants from the Same Donors. Annals of Internal Medicine, 1991, 114, 954-955.	3.9	243
29	Regulatory functions of CD8+CD28â€“ T cells in an autoimmune disease model. Journal of Clinical Investigation, 2003, 112, 1037-1048.	8.2	236
30	Maternal Acceptance of the Fetus: True Human Tolerance. Journal of Immunology, 2007, 178, 3345-3351.	0.8	222
31	CD4+ T Cells Mediate Abscess Formation in Intra-abdominal Sepsis by an IL-17-Dependent Mechanism. Journal of Immunology, 2003, 170, 1958-1963.	0.8	216
32	Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter. Journal of Biological Chemistry, 2003, 278, 47156-47165.	3.4	209
33	Regulatory CD25+ T Cells in Human Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 1643-1651.	6.1	208
34	Proinflammatory functions of vascular endothelial growth factor in alloimmunity. Journal of Clinical Investigation, 2003, 112, 1655-1665.	8.2	203
35	T-cell costimulatory pathways in allograft rejection and tolerance. Immunological Reviews, 2003, 196, 85-108.	6.0	202
36	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. Immunity, 2004, 20, 529-538.	14.3	202

#	Article	IF	Citations
37	Allograft rejection mediated by memory T cells is resistant to regulation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19954-19959.	7.1	189
38	Costimulatory pathways in transplantation: challenges and new developments. Immunological Reviews, 2009, 229, 271-293.	6.0	189
39	MECHANISMS OF T CELL RECOGNITION OF ALLOANTIGEN. Transplantation, 1994, 57, 1295-1302.	1.0	181
40	PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection. Journal of Immunology, 2007, 179, 5204-5210.	0.8	176
41	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 108, 739-747.	8.2	168
42	Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 3408-3415.	0.8	164
43	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.8	159
44	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158
45	Memory T Cells: A Hurdle to Immunologic Tolerance. Journal of the American Society of Nephrology: JASN, 2003, 14, 2402-2410.	6.1	155
46	Role of Indirect Allorecognition in Allograft Rejection. International Reviews of Immunology, 1996, 13, 221-229.	3.3	146
47	The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance. Journal of Immunology, 2011, 187, 4530-4541.	0.8	145
48	The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation. Journal of the American Society of Nephrology: JASN, 2002, 13, 559-575.	6.1	141
49	Is the Administration of Dopamine Associated with Adverse or Favorable Outcomes in Acute Renal Failure?. American Journal of Medicine, 1996, 101, 49-53.	1.5	140
50	Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 6648-6656.	0.8	139
51	Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It. Journal of Immunology, 2006, 176, 4632-4639.	0.8	139
52	Congenic Mesenchymal Stem Cell Therapy Reverses Hyperglycemia in Experimental Type 1 Diabetes. Diabetes, 2010, 59, 3139-3147.	0.6	139
53	A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance. Journal of Immunology, 2007, 179, 5211-5219.	0.8	136
54	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1993, 56, 461-465.	1.0	133

#	ARTICLE	IF	CITATIONS
55	UPREGULATION OF CYTOKINES ASSOCIATED WITH MACROPHAGE ACTIVATION IN THE LEWIS-TO-F344 RAT TRANSPLANTATION MODEL OF CHRONIC CARDIAC REJECTION1,2. Transplantation, 1995, 59, 572-578.	1.0	133
56	Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes. Diabetes, 2008, 57, 3013-3024.	0.6	126
57	The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. Journal of Clinical Investigation, 2000, 106, 63-72.	8.2	125
58	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1994, 58, 125-132.	1.0	124
59	Cutting Edge: Recipient MHC Class II Expression Is Required to Achieve Long-Term Survival of Murine Cardiac Allografts After Costimulatory Blockade. Journal of Immunology, 2001, 167, 5522-5526.	0.8	123
60	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.8	122
61	Critical, but Conditional, Role of OX40 in Memory T Cell-Mediated Rejection. Journal of Immunology, 2006, 176, 1394-1401.	0.8	118
62	Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. Journal of Experimental Medicine, 2007, 204, 1691-1702.	8.5	117
63	Enzyme-Linked Immunosorbent Spot Assay Analysis of Peripheral Blood Lymphocyte Reactivity to Donor HLA-DR Peptides. Journal of the American Society of Nephrology: JASN, 2002, 13, 252-259.	6.1	117
64	Specificity of CD4+CD25+ Regulatory T Cell Function in Alloimmunity. Journal of Immunology, 2006, 176, 329-334.	0.8	116
65	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. Journal of Immunology, 2011, 187, 1113-1119.	0.8	115
66	ORAL, BUT NOT INTRAVENOUS, ALLOANTIGEN PREVENTS ACCELERATED ALLOGRAFT REJECTION BY SELECTIVE INTRAGRAFT TH2 CELL ACTIVATION. Transplantation, 1993, 55, 1112-1117.	1.0	114
67	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	6.1	114
68	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	8.2	114
69	CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nature Immunology, 2001, 2, 58-63.	14.5	113
70	Endothelial Cells Modify the Costimulatory Capacity of Transmigrating Leukocytes and Promote Cd28-Mediated Cd4+ T Cell Alloactivation. Journal of Experimental Medicine, 1999, 190, 555-566.	8.5	111
71	Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clinical Immunology, 2007, 125, 16-25.	3.2	111
72	Peripheral Deletion After Bone Marrow Transplantation with Costimulatory Blockade Has Features of Both Activation-Induced Cell Death and Passive Cell Death. Journal of Immunology, 2001, 166, 2311-2316.	0.8	110

#	Article	IF	Citations
73	CD28-independent Costimulation of T Cells in Alloimmune Responses. Journal of Immunology, 2001, 167, 140-146.	0.8	109
74	T-Cell Costimulatory Pathways in Allograft Rejection and Tolerance. Transplantation, 2005, 80, 555-563.	1.0	108
75	ANTI-CD154 OR CTLA4Ig OBVIATES THE NEED FOR THYMIC IRRADIATION IN A NON-MYELOABLATIVE CONDITIONING REGIMEN FOR THE INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AND TOLERANCE1. Transplantation, 1999, 68, 1348-1355.	1.0	108
76	DONOR ANTIGEN IS NECESSARY FOR THE PREVENTION OF CHRONIC REJECTION IN CTLA4IG-TREATED MURINE CARDIAC ALLOGRAFT RECIPIENTS1,2. Transplantation, 1997, 64, 1646-1650.	1.0	103
77	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney International, 2003, 64, 1685-1694.	5.2	102
78	Challenges to achieving clinical transplantation tolerance. Journal of Clinical Investigation, 2001, 108, 943-948.	8.2	101
79	Critical Role of OX40 in CD28 and CD154-Independent Rejection. Journal of Immunology, 2004, 172, 1691-1698.	0.8	99
80	CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury: Rapid Communication. Kidney International, 1997, 52, 1678-1684.	5.2	98
81	Chronic Rejection in Experimental Cardiac Transplantation: Studies in the Lewis-F344 Model. Immunological Reviews, 1993, 134, 5-19.	6.0	96
82	The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. Journal of Clinical Investigation, 2008, 118, 742-751.	8.2	93
83	Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7. Circulation, 2013, 127, 463-475.	1.6	91
84	Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models. Journal of Immunology, 2001, 166, 322-329.	0.8	90
85	Neural Stem/Progenitor Cells Express Costimulatory Molecules That Are Differentially Regulated by Inflammatory and Apoptotic Stimuli. American Journal of Pathology, 2004, 164, 1615-1625.	3.8	90
86	Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy. Circulation, 2008, 117, 660-669.	1.6	89
87	Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. Journal of Clinical Investigation, 2001, 107, 909-916.	8.2	89
88	CD70 Signaling Is Critical for CD28-Independent CD8+T Cell-Mediated Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 1357-1364.	0.8	88
89	MECHANISMS OF ALLO-RECOGNITION. Transplantation, 1994, 57, 572-576.	1.0	87
90	CD4+ T Cells Regulate Surgical and Postinfectious Adhesion Formation. Journal of Experimental Medicine, 2002, 195, 1471-1478.	8.5	87

#	Article	IF	Citations
91	CTLA4-Ig: a novel immunosuppressive agent. Expert Opinion on Investigational Drugs, 2000, 9, 2147-2157.	4.1	86
92	The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo. Journal of Immunology, 2003, 170, 2949-2955.	0.8	86
93	Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney International, 1999, 56, 1967-1979.	5.2	85
94	New Insights Into the Interactions Between T-Cell Costimulatory Blockade and Conventional Immunosuppressive Drugs. Annals of Surgery, 2002, 236, 667-675.	4.2	84
95	THE CD154-CD40 COSTIMULATORY PATHWAY IN TRANSPLANTATION. Transplantation, 2002, 73, S36-S39.	1.0	83
96	The Role of CC Chemokine Receptor 5 (CCR5) in Islet Allograft Rejection. Diabetes, 2002, 51, 2489-2495.	0.6	82
97	Mechanisms Underlying Blockade of Allograft Acceptance by TLR Ligands. Journal of Immunology, 2008, 181, 1692-1699.	0.8	82
98	Immunomodulatory functions of mesenchymal stem cells. Lancet, The, 2004, 363, 1411-1412.	13.7	81
99	Costimulatory pathways in transplantation. Seminars in Immunology, 2011, 23, 293-303.	5.6	80
100	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes, 2015, 64, 158-171.	0.6	80
101	Physiological Mechanisms of Regulating Alloimmunity: Cytokines, CTLA-4, CD25+ Cells, and the Alloreactive T Cell Clone Size. Journal of Immunology, 2002, 169, 3744-3751.	0.8	78
102	Differential Role of CCR2 in Islet and Heart Allograft Rejection: Tissue Specificity of Chemokine/Chemokine Receptor Function In Vivo. Journal of Immunology, 2004, 172, 767-775.	0.8	74
103	Peptide-mediated immunosuppression. Current Opinion in Immunology, 1997, 9, 669-675.	5.5	73
104	Indirect Allorecognition of Mismatched Donor HLA Class II Peptides in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome. American Journal of Transplantation, 2001, 1, 228-235.	4.7	73
105	Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection. Diabetes, 2013, 62, 1665-1675.	0.6	73
106	Alloreactive T Cell Responses and Acute Rejection of Single Class II MHC-Disparate Heart Allografts Are under Strict Regulation by CD4+CD25+ T Cells. Journal of Immunology, 2005, 174, 3741-3748.	0.8	72
107	Role of CXC Chemokine Receptor 3 Pathway in Renal Ischemic Injury. Journal of the American Society of Nephrology: JASN, 2006, 17, 716-723.	6.1	72
108	Hepatocyte Growth Factor Prevents the Development of Chronic Allograft Nephropathy in Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 1280-1292.	6.1	72

#	Article	IF	Citations
109	THE INDIRECT PATHWAY OF ALLORECOGNITION. Transplantation, 1995, 59, 612-616.	1.0	71
110	Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. Journal of Immunology, 2003, 171, 5673-5677.	0.8	71
111	Targeting the CXCR4â€"CXCL12 Axis Mobilizes Autologous Hematopoietic Stem Cells and Prolongs Islet Allograft Survival via Programmed Death Ligand 1. Journal of Immunology, 2011, 186, 121-131.	0.8	71
112	A rendezvous before rejection: Where do T cells meet transplant antigens?. Nature Medicine, 2002, 8, 220-222.	30.7	70
113	Clinical Transplantation Tolerance: Many Rivers to Cross. Journal of Immunology, 2007, 178, 5419-5423.	0.8	69
114	CD28-independent induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 107, 575-583.	8.2	69
115	Avoidance of Cyclosporine in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1903-1909.	6.1	67
116	CELLULAR AND HUMORAL MECHANISMS OF VASCULARIZED ALLOGRAFT REJECTION INDUCED BY INDIRECT RECOGNITION OF DONOR MHC ALLOPEPTIDES1. Transplantation, 1999, 67, 1523-1532.	1.0	65
117	Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10734-10739.	7.1	64
118	Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. Journal of Clinical Investigation, 2002, 109, 1471-1479.	8.2	64
119	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. Journal of Immunology, 2000, 164, 4649-4658.	0.8	63
120	CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection. American Journal of Pathology, 2001, 158, 977-986.	3.8	63
121	Specific MDR1 P-Glycoprotein Blockade Inhibits Human Alloimmune T Cell Activation In Vitro. Journal of Immunology, 2001, 166, 2451-2459.	0.8	62
122	DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY CURES NEW-ONSET DIABETES, PREVENTS RECURRENT AUTOIMMUNE DIABETES, AND DELAYS ALLOGRAFT REJECTION IN NONOBESE DIABETIC MICE1. Transplantation, 2004, 77, 990-997.	1.0	62
123	Immunosuppressive Drugs and Tregs. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1661-1669.	4.5	62
124	A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice. Diabetes, 2010, 59, 2253-2264.	0.6	62
125	The Role of Autoimmunity in Islet Allograft Destruction: Major Histocompatibility Complex Class II Matching Is Necessary for Autoimmune Destruction of Allogeneic Islet Transplants After T-Cell Costimulatory Blockade. Diabetes, 2002, 51, 3202-3210.	0.6	60
126	Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2008, 173, 411-422.	3.8	59

#	Article	IF	Citations
127	The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Human Immunology, 2002, 63, 912-925.	2.4	58
128	New Reagents on the Horizon for Immune Tolerance. Annual Review of Medicine, 2007, 58, 329-346.	12.2	58
129	Finally, CTLA4Ig graduates to the clinic. Journal of Clinical Investigation, 1999, 103, 1223-1225.	8.2	58
130	T-CELL COSTIMULATORY BLOCKADE IN EXPERIMENTAL CHRONIC CARDIAC ALLOGRAFT REJECTION. Transplantation, 1997, 63, 1053-1058.	1.0	56
131	Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes. PLoS ONE, 2014, 9, e89561.	2.5	54
132	ROLE OF INDIRECT ALLORECOGNITION IN EXPERIMENTAL LATE ACUTE REJECTION1,2. Transplantation, 1997, 64, 1823-1828.	1.0	54
133	Allograft Rejection in a New Allospecific CD4+ TCR Transgenic Mouse. American Journal of Transplantation, 2003, 3, 381-389.	4.7	52
134	Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clinical Immunology, 2008, 126, 140-147.	3.2	52
135	CHRONIC BLOCKADE OF CD28-B7-MEDIATED T-CELL COSTIMULATION BY CTLA4Ig REDUCES INTIMAL THICKENING IN MHC CLASS I AND II INCOMPATIBLE MOUSE HEART ALLOGRAFTS1,2. Transplantation, 1997, 64, 1641-1645.	1.0	52
136	ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Reports, 2015, 12, 1564-1574.	6.4	51
137	THE EFFECTS OF NONDEPLETING CD4 TARGETED THERAPY IN PRESENSITIZED RAT RECIPIENTS OF CARDIAC ALLOGRAFTS1,2. Transplantation, 1996, 61, 804-811.	1.0	50
138	MECHANISMS OF INDIRECT ALLORECOGNITION IN GRAFT REJECTION. Transplantation, 1996, 62, 705-710.	1.0	50
139	ACQUIRED SYSTEMIC TOLERANCE TO RAT CARDIAC ALLOGRAFTS INDUCED BY INTRATHYMIC INOCULATION OF SYNTHETIC POLYMORPHIC MHC CLASS I ALLOPEPTIDES1,2. Transplantation, 1996, 62, 1878-1882.	1.0	50
140	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	8.2	50
141	Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 519-527.	6.1	47
142	Blockade of CD28-B7, But Not CD40-CD154, Prevents Costimulation of Allogeneic Porcine and Xenogeneic Human Anti-Porcine T Cell Responses. Journal of Immunology, 2000, 164, 3434-3444.	0.8	45
143	Bacterial Pathogens Induce Abscess Formation by CD4 + T-Cell Activation via the CD28â€"B7-2 Costimulatory Pathway. Infection and Immunity, 2000, 68, 6650-6655.	2.2	44
144	MECHANISMS OF INDIRECT ALLORECOGNITION. Transplantation, 1998, 65, 876-883.	1.0	44

#	Article	IF	Citations
145	Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood, 2011, 117, 1176-1183.	1.4	43
146	Rejection of Mouse Cardiac Allografts by Costimulation in <i>trans</i>. Journal of Immunology, 2001, 167, 1174-1178.	0.8	42
147	T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection1. Transplantation, 2002, 74, 1053-1057.	1.0	42
148	Modulation of surgical fibrosis by microbial zwitterionic polysaccharides. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16753-16758.	7.1	42
149	Indirect Allorecognition of Donor Class I and II Major Histocompatibility Complex Peptides Promotes the Development of Transplant Vasculopathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2500-2506.	6.1	42
150	Transplantation tolerance: The concept and its applicability. Pediatric Transplantation, 1999, 3, 181-192.	1.0	41
151	Allorecognition and Effector Pathways of Islet Allograft Rejection in Normal versus Nonobese Diabetic Mice. Journal of the American Society of Nephrology: JASN, 2003, 14, 2168-2175.	6.1	41
152	A Novel Alloantigen-Specific CD8+PD1+ Regulatory T Cell Induced by ICOS-B7h Blockade In Vivo. Journal of Immunology, 2007, 179, 786-796.	0.8	41
153	Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells. Gastroenterology, 1994, 107, 1537-1542.	1.3	40
154	Mechanism of Action of Donor-Specific Transfusion in Inducing Tolerance: Role of Donor MHC Molecules, Donor Co-stimulatory Molecules, and Indirect Antigen Presentation. Journal of the American Society of Nephrology: JASN, 2004, 15, 2423-2428.	6.1	40
155	A Novel Clinically Relevant Approach to Tip the Balance Toward Regulation in Stringent Transplant Model. Transplantation, 2010, 90, 260-269.	1.0	40
156	The CD154-CD40 T Cell Costimulation Pathway Is Required for Host Sensitization of CD8+ T Cells by Skin Grafts Via Direct Antigen Presentation. Journal of Immunology, 2002, 169, 1270-1276.	0.8	39
157	Further Analysis of the T-Cell Subsets and Pathways of Murine Cardiac Allograft Rejection. American Journal of Transplantation, 2003, 3, 23-27.	4.7	39
158	Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13230-13235.	7.1	39
159	Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. Journal of Clinical Investigation, 2002, 109, 1471-1479.	8.2	39
160	Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1999, 96, 158-166.	2.3	38
161	Different Costimulatory and Growth Factor Requirements for CD4+and CD8+T Cell-Mediated Rejection. Journal of Immunology, 2004, 173, 214-221.	0.8	38
162	COMPARATIVE STUDIES OF SPECIFIC ACQUIRED SYSTEMIC TOLERANCE INDUCED BY INTRATHYMIC INOCULATION OF A SINGLE SYNTHETIC WISTAR-FURTH (RT1U) ALLO-MHC CLASS I (RT1.AU) PEPTIDE OR WAG (RT1U)-DERIVED CLASS I PEPTIDE1. Transplantation, 1998, 66, 1059-1066.	1.0	38

#	Article	IF	Citations
163	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
164	Tolerance and chronic rejection. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 727-738.	4.0	36
165	Mechanisms of targeting cd28 by a signaling monoclonal antibody in acute and chronic allograft rejection1. Transplantation, 2002, 73, 1310-1317.	1.0	34
166	Novel Insights into the Mechanism of Action of FTY720 in a Transgenic Model of Allograft Rejection: Implications for Therapy of Chronic Rejection. Journal of Immunology, 2006, 176, 36-42.	0.8	34
167	Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney International, 2002, 62, 627-631.	5.2	33
168	Intact <scp>B</scp>7â€‹<scp>H</scp>3 signaling promotes allograft prolongation through preferential suppression of <scp>T</scp>h1 effector responses. European Journal of Immunology, 2012, 42, 2343-2353.	2.9	33
169	Matrix Embedding Alters the Immune Response Against Endothelial Cells In Vitro and In Vivo. Circulation, 2005, 112, I89-95.	1.6	33
170	In VivoMechanisms of Acquired Thymic Tolerance. Cellular Immunology, 1997, 179, 165-173.	3.0	32
171	Interaction Between ICOS-B7RP1 and B7-CD28 Costimulatory Pathways in Alloimmune Responses In Vivo. American Journal of Transplantation, 2003, 3, 390-395.	4.7	32
172	The Novel Role of SERPINB9 in Cytotoxic Protection of Human Mesenchymal Stem Cells. Journal of Immunology, 2011, 187, 2252-2260.	0.8	32
173	T CELL RECOGNITION OF XENO-MHC PEPTIDES DURING CONCORDANT XENOGRAFT REJECTION1. Transplantation, 1996, 61, 1133-1137.	1.0	32
174	Inhibition of allorecognition by a human class II MHCâ€"derived peptide through the induction of apoptosis. Journal of Clinical Investigation, 1999, 103, 859-867.	8.2	32
175	New TCR Transgenic Model for Tracking Allospecific CD4 Tâ€Cell Activation and Tolerancein Vivo. American Journal of Transplantation, 2003, 3, 1242-1250.	4.7	31
176	Clinical update: immunosuppression minimisation. Lancet, The, 2007, 369, 1676-1678.	13.7	31
177	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. Journal of Clinical Investigation, 2018, 128, 3490-3503.	8.2	31
178	Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 639-647.	4.0	30
179	Immune Profile of Pediatric Renal Transplant Recipients following Alemtuzumab Induction. Journal of the American Society of Nephrology: JASN, 2012, 23, 174-182.	6.1	30
180	CTLA4Ig-Induced Linked Regulation of Allogeneic T Cell Responses. Journal of Immunology, 2001, 166, 1572-1582.	0.8	29

#	Article	IF	Citations
181	The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Current Opinion in Urology, 2000, 10, 57-62.	1.8	27
182	Role of the ICOS-B7h Costimulatory Pathway in the Pathophysiology of Chronic Allograft Rejection. Transplantation, 2005, 79, 1045-1050.	1.0	26
183	SYNTHETIC MHC CLASS I PEPTIDE PROLONGS CARDIAC SURVIVAL AND ATTENUATES TRANSPLANT ARTERIOSCLEROSIS IN THE LEWIS???FISCHER 344 MODEL OF CHRONIC ALLOGRAFT REJECTION. Transplantation, 1997, 64, 14-19.	1.0	26
184	The Allocation of Cadaver Kidneys for Transplantation in the United States. Journal of the American Society of Nephrology: JASN, 1999, 10, 2237-2243.	6.1	26
185	Mechanisms of Tolerance Induced by Donor-Specific Transfusion and ICOS-B7h Blockade in a Model of CD4+ T-Cell-Mediated Allograft Rejection. American Journal of Transplantation, 2005, 5, 31-39.	4.7	25
186	CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival. PLoS ONE, 2013, 8, e60391.	2.5	25
187	Mechanisms of Oral Tolerance by MHC Peptides. Annals of the New York Academy of Sciences, 1996, 778, 338-345.	3.8	24
188	Defining Th1 and Th2 Immune Responses in a Reciprocal Cytokine Environment In Vivo. Journal of Immunology, 2004, 172, 4260-4265.	0.8	24
189	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. Journal of Immunology, 2004, 172, 5774-5781.	0.8	24
190	Induction of Robust Diabetes Resistance and Prevention of Recurrent Type 1 Diabetes Following Islet Transplantation by Gene Therapy. Journal of Immunology, 2007, 179, 6762-6769.	0.8	24
191	Immunomodulatory Functions of Low-Molecular Weight Hyaluronate in an Acute Rat Renal Allograft Rejection Model. Journal of the American Society of Nephrology: JASN, 1999, 10, 1059-1066.	6.1	24
192	T-cell co-stimulatory blockade in transplantation: two steps forward one step back!. Expert Opinion on Biological Therapy, 2013, 13, 1557-1568.	3.1	23
193	Blocking Costimulatory Signals to Induce Transplantation Tolerance and Prevent Autoimmune Disease. International Reviews of Immunology, 1999, 18, 185-199.	3.3	22
194	CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy1. Transplantation, 2003, 75, 1142-1146.	1.0	22
195	Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in alloâ€•and xenogeneic models. FASEB Journal, 2007, 21, 1515-1526.	0.5	22
196	Membranous Lupus Nephritis in a Renal Allograft: Response to Mycophenolate Mofetil Therapy. American Journal of Transplantation, 2001, 1, 288-292.	4.7	21
197	A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection1. Transplantation, 2002, 73, 1736-1742.	1.0	21
198	Clinical transplantation tolerance: The promise and challenges. Kidney International, 2004, 65, 1560-1563.	5.2	19

#	Article	IF	Citations
199	Alternative T-Cell Costimulatory Pathways in Transplant Rejection and Tolerance Induction: Hierarchy or Redundancy?. American Journal of Transplantation, 2003, 3, 509-511.	4.7	18
200	Indirect Recognition of MHC Class I Allopeptides Accelerates Lung Allograft Rejection in Miniature Swine. American Journal of Transplantation, 2005, 5, 1626-1634.	4.7	18
201	Negative T-cell costimulatory pathways: their role in regulating alloimmune responses. Current Opinion in Organ Transplantation, 2008, 13, 373-378.	1.6	17
202	Regulatory T Cells Maintain Peripheral Tolerance to Islet Allografts Induced by Intrathymic Injection of MHC Class I Allopeptides. Cell Transplantation, 1999, 8, 375-381.	2.5	15
203	Case 8-2003. New England Journal of Medicine, 2003, 348, 1033-1044.	27.0	13
204	TNP-470, an Angiogenesis Inhibitor, Attenuates the Development of Allograft Vasculopathy. Transplantation, 2004, 78, 1218-1221.	1.0	13
205	Inotuzumab Ozogamicin Murine Analog-Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses. Diabetes, 2012, 61, 155-165.	0.6	13
206	B cell-targeted therapies in autoimmunity: rationale and progress. F1000 Biology Reports, 2009, 1, 39.	4.0	13
207	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.6	12
208	Sijilli: a mobile electronic health records system for refugees in low-resource settings. The Lancet Global Health, 2019, 7, e1168-e1169.	6.3	11
209	Costimulation couture: a designer approach to regulating autoimmunity. Journal of Clinical Investigation, 2006, 116, 2080-2083.	8.2	11
210	Transplantation tolerance in pediatric recipients: Lessons and challenges. Pediatric Transplantation, 2005, 9, 17-27.	1.0	10
211	T-cell recognition of allograft target antigens. Current Opinion in Organ Transplantation, 2000, 5, 23-28.	1.6	9
212	Measuring T Cell Alloreactivity to Predict Kidney Transplant Outcomes: Are We There Yet?. Journal of the American Society of Nephrology: JASN, 2006, 17, 328-330.	6.1	9
213	TIM4 Regulates the Anti-Islet Th2 Alloimmune Response. Cell Transplantation, 2015, 24, 1599-1614.	2.5	9
214	Use of polyclonal/monoclonal antibody therapies in transplantation. Expert Opinion on Biological Therapy, 2017, 17, 339-352.	3.1	9
215	Why do we reject a graft? Mechanisms of recognition of transplantation antigens. Transplantation Reviews, 1996, 10, 150-159.	2.9	8
216	A Novel Mechanism for the Immunomodulatory Functions of Class II MHCâ€“Derived Peptides. Journal of the American Society of Nephrology: JASN, 2003, 14, 1053-1065.	6.1	8

#	Article	IF	Citations
217	Targeting CD28 to prevent transplant rejection. Expert Opinion on Therapeutic Targets, 2014, 18, 225-242.	3.4	8
218	Costimulation Blockade in Transplantation. Advances in Experimental Medicine and Biology, 2019, 1189, 267-312.	1.6	8
219	Overcoming cardiac allograft vasculopathy (CAV) by inducing tolerance. Frontiers in Bioscience - Landmark, 2002, 7, e116.	3.0	7
220	Donor Antigen and Transplant Tolerance Strategies: It Takes Two to Tango!. Journal of the American Society of Nephrology: JASN, 2004, 15, 1101-1103.	6.1	7
221	Clinical Transplantation Tolerance: A Myth No More, Butâ€¦. American Journal of Kidney Diseases, 2009, 54, 1005-1011.	1.9	7
222	Role of Nuclear Factor of Activated T Cell (NFAT) Transcription Factors in Skin and Vascularized Cardiac Allograft Rejection. Transplantation, 2011, 92, e26-e27.	1.0	7
223	Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways. Journal of Heart and Lung Transplantation, 2000, 19, 566-575.	0.6	6
224	A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients. Clinical Transplantation, 2008, 22, 754-759.	1.6	6
225	A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochemical and Biophysical Research Communications, 2010, 394, 646-652.	2.1	6
226	The Limits of Linked Suppression for Regulatory T Cells. Frontiers in Immunology, 2016, 7, 82.	4.8	5
227	Live Images of Donor Dendritic Cells Trafficking via CX3CR1 Pathway. Frontiers in Immunology, 2016, 7, 412.	4.8	5
228	Major histocompatibility complexâ€“derived peptides as novel forms of immunosuppression. Current Opinion in Organ Transplantation, 1999, 4, 211-218.	1.6	5
229	Challenges for the translation of T cell costimulatory blockade therapies to the clinic. Expert Opinion on Biological Therapy, 2002, 2, 453-457.	3.1	4
230	The arduous road to achieving an immunosuppression-free state in kidney transplant recipients. Nature Clinical Practice Nephrology, 2007, 3, 464-465.	2.0	4
231	Regulating rejection with cell therapy. Nature Biotechnology, 2008, 26, 191-192.	17.5	4
232	T-cell co-stimulatory blockade in kidney transplantation: back to the bench. Kidney International Supplements, 2011, 1, 25-30.	14.2	4
233	T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clinics in Dermatology, 2001, 19, 586-591.	1.6	3
234	Transplantation Tolerance. , 2004, 146, 95-104.		3

#	Article	IF	Citations
235	Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nature Clinical Practice Nephrology, 2006, 2, 134-135.	2.0	3
236	T cell costimulatory pathways in allograft rejection and tolerance: what's new?. Current Opinion in Organ Transplantation, 2007, 12, 17-22.	1.6	3
237	Imaging cell biology in transplantation. Transplant International, 2016, 29, 1349-1351.	1.6	3
238	Anti-CD3 mAb treatment cures PDL1â˜'/â˜'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	3.2	2
239	Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans. American Journal of Pathology, 2017, 187, 1368-1379.	3.8	2
240	Overview: Future Approaches to Renal Replacement and Regeneration. Journal of the American Society of Nephrology: JASN, 2004, 15, 1105-1105.	6.1	1
241	Tolerance is the achievable â€˜Holy Grailâ€™ in transplantation. Current Opinion in Organ Transplantation, 2006, 11, 24-29.	1.6	1
242	Harnessing negative T-cell costimulatory pathways to promote engraftment. Transplant International, 2008, 21, 18-20.	1.6	1
243	BCL-Xl AUGMENTS T CELL SURVIVAL IN THE ABSENCE OF COSTIMULATION AND BLOCKS IMMUNOSUPPRESSION WITH CTLA4IG.. Transplantation, 1998, 65, 79.	1.0	1
244	Role of novel T-cell costimulatory pathways in transplantation. Current Opinion in Organ Transplantation, 2003, 8, 25-33.	1.6	0
245	Induced costimulatory molecule-B7h costimulatory pathway in alloimmune regulation. Current Opinion in Organ Transplantation, 2005, 10, 186-190.	1.6	0
246	CD28: beyond just T-cell costimulation. Blood, 2007, 109, 2668-2669.	1.4	0
247	Understanding How Tregs Are Regulated: Therapeutic Implications. Transplantation, 2009, 88, 1159-1160.	1.0	0
248	Transplantation Immunobiology. , 2010, , 477-490.		0
249	Introduction: Conflict Nephrology Revisited. Seminars in Nephrology, 2020, 40, 338-340.	1.6	0
250	Tolerance: Is it time to Move to the Clinic?. , 2001, , 293-313.		0
251	Immune Tolerance. , 2001, , 73-90.		0
252	Novel Strategies Using MHC Peptides. , 2001, , 101-126.		0

#	Article	IF	Citations
253	Allorecognition Pathways. , 0, , 12-20.		0